Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mix of positive and negative indicators. The company's strategic focus on innovative cancer therapies and strong market trends are promising. However, the lack of specific revenue guidance and increased expenses raise concerns. The Q&A section reveals positive enrollment and safety profile feedback, but management's vague responses on certain issues may cause uncertainty. Overall, the neutral sentiment reflects the balance between potential growth and existing uncertainties.
Key Financial Performance
Cash, Cash Equivalents, and Investments $266.9 million as of March 31, 2026. This was strengthened by a public offering in April, generating approximately $200.4 million in gross proceeds, extending the cash runway into the first quarter of 2029.
R&D Expenses $32 million for the first quarter of 2026, including $2.7 million of noncash stock-based compensation. This reflects continued investment in clinical programs.
G&A Expenses $14.1 million for the first quarter of 2026, including $5.6 million in noncash stock-based compensation.
Net Loss $42.6 million for the first quarter of 2026, or $0.18 per share, including noncash stock-based compensation expense of $8.3 million.
Operating Cash Expense Guidance Increased from approximately $150 million to $165 million for 2026, reflecting the overall timing of the ALPHA3 program.
GAAP Operating Expenses Guidance Increased from approximately $210 million to $225 million for 2026, including estimated noncash stock-based compensation expense of approximately $35 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Cema-cel: Achieved a 58.3% MRD clearance rate in the ALPHA3 trial for large B-cell lymphoma, compared to 16.7% in the observation arm. Demonstrated a favorable safety profile with no CRS, ICANS, or treatment-related hospitalizations, enabling outpatient management.
ALLO-329: Progressing through early clinical development for autoimmune indications. Initial signs of clinical activity and favorable tolerability observed in the RESOLUTION basket trial.
Global Expansion of ALPHA3: Regulatory approval in Australia and South Korea, expanding the study footprint to over 80 sites worldwide. Approximately one-third of screening and treatments conducted in community cancer centers.
Financial Position: Cash, cash equivalents, and investments totaled $266.9 million as of March 31, 2026. Public offering in April generated $200.4 million in gross proceeds, extending cash runway into Q1 2029.
R&D and G&A Expenses: R&D expenses for Q1 2026 were $32 million, and G&A expenses were $14.1 million. Operating cash expense guidance for 2026 increased to $165 million.
Outpatient CAR-T Administration: ALPHA3 trial results suggest a shift towards outpatient CAR-T administration, potentially enabling broader use in community practices.
Dagger Technology in ALLO-329: Designed to overcome premature rejection of allogeneic CAR T cells, validated in metastatic solid tumor settings, and now applied to autoimmune diseases.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approval and Expansion: The company is expanding its clinical trial footprint globally, including Australia and South Korea. However, regulatory approvals and operational execution in these regions could pose challenges.
Clinical Trial Execution: The ALPHA3 and ALLO-329 programs require precise execution, including patient enrollment, dose escalation, and safety monitoring. Any delays or issues in trial execution could impact timelines and outcomes.
Safety and Tolerability: While early results show favorable safety profiles, any unforeseen adverse events in later stages of trials could hinder the development and approval of the therapies.
Financial Sustainability: The company has increased its operating cash expense guidance for 2026, which could strain financial resources if milestones are not met as planned.
Market Adoption: The success of cema-cel and ALLO-329 depends on their adoption in outpatient and community settings, which may face resistance or logistical challenges.
Technological Validation: The Dagger technology and other innovations are still in early stages of validation. Any failure to demonstrate efficacy or safety could impact the company's strategic objectives.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
ALPHA3 Program: The ALPHA3 program is advancing towards an interim event-free survival (EFS) analysis in mid-2027. The program aims to establish cema-cel as a treatment for large B-cell lymphoma in the first-line consolidation setting, with a focus on outpatient administration and broader accessibility. The trial is expanding globally, with over 80 sites expected worldwide, including new activations in Australia and South Korea.
ALLO-329 Program: The ALLO-329 program is progressing through early clinical development for autoimmune indications. Dose escalation and patient follow-up are ongoing, with a comprehensive update expected in the fourth quarter of 2026. The program incorporates Dagger technology to overcome premature rejection of allogeneic CAR T cells and aims to establish a tolerability profile and early signs of clinical activity.
Financial Guidance: Operating cash expense guidance for 2026 has been increased from $150 million to $165 million, and GAAP operating expenses are expected to rise from $210 million to $225 million. The company has extended its cash runway into the first quarter of 2029 following a public offering that generated $200.4 million in gross proceeds.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about the initial signs of activity or B-cell reductions in the lymphodepletion cohort compared to other cohorts?
A:The details will be shared in the Q4 update. Encouraging signs are observed in cohorts with and without lymphodepletion (LD). Enrollment is progressing briskly.
Q:How has the announcement of MRD negativity interim results impacted enrollment and engagement in the DLBCL program?
A:The announcement has stimulated increased activity, with new sites expressing interest in participating in ALPHA3. Screening and enrollment pace has been going well.
Q:What sort of safety profile do you hope to achieve with ALLO-329 over the long term?
A:The goal is a clean safety profile, allowing outpatient treatment and management. Early results from 20 million and 40 million dose levels with cyclophosphamide lymphodepletion are encouraging.
Q:What should we expect in the Q4 update for ALLO-329?
A:The update will include data from 20 million, 40 million, and potentially higher dose levels, with and without cyclophosphamide. Enrollment has been robust, with 9 patients enrolled in 6 months.
Q:Will the Q4 update include data across 20 million and 40 million cell doses or higher doses?
A:The Q4 update will include data from 20 million, 40 million, and potentially higher doses. The study is progressing with dose escalation.
Q:What is the patient composition across SLE, myositis, and sclerosis in the Q4 update?
A:Patients come from lupus, inflammatory myopathies, and scleroderma. The mix will be presented in Q4, and no changes to the basket-style design are planned.
Q:Why was the target enrollment for the trial increased from 54 to 66 patients?
A:The change was administrative and did not involve any changes to the study design.
Q:What feedback are you hearing from community practices regarding cema-cel?
A:Feedback has been overwhelmingly positive. Community practices are interested in participating due to the clean safety profile and ease of patient management.
Q:What is the progress on site activation and patient enrollment for ALLO-329?
A:Site activation is nearing completion, with excellent traction even in a competitive space. Screening and enrollment are progressing well.
Q:What are your thoughts on dosing for ALLO-329 going forward?
A:Dose escalation will continue until safety limits are reached. Adjustments are not planned, and the next dose level is 80 million cells.
Q:What is your current cash runway, and what does it cover?
A:The cash runway extends into Q1 2029, covering the completion of the ALPHA3 study and the Phase I resolution study for ALLO-329.
Q:What are the decision factors for adding fludarabine to the ALLO-329 protocol?
A:The decision will be data-driven and based on patient demand. The primary focus is on dose escalation.
Q:What are your expectations for T cell repopulation after ALLO-329 treatment?
A:The study will analyze B cell and T cell repertoire changes. CD70-positive pathogenic T cells are targeted, and results will be shared in Q4 if available.
Q:How many doses could you escalate in the ALLO-329 study, and what is the next step?
A:The next dose level is 80 million cells. Further dose escalation details will be shared in the Q4 update.
Q:What are the efficacy and safety benchmarks for ALLO-329 compared to other therapies?
A:The goal is outpatient treatment with a clean safety profile and the possibility of redosing years later. This profile is competitive with emerging modalities.
Q:Why was the autoimmune resolution data update moved to Q4?
A:The decision was made to provide a more meaningful update with data from higher dose levels, as enrollment is progressing briskly.
Q:Review of Unclear Management Responses
A:Management avoided directly answering why the target enrollment for the trial was increased from 54 to 66 patients, stating it was an administrative change without providing further details.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ALLO
CAR
CD
EFS
MRD clearance
approach
cel
cell
ctDNA level
design
development
disease
dos
dose
escalation
evidence
futility analysis
goal
interest study
observation arm
outpatient setting
patient level
point
program
reduction
rejection
safety
screening
sign activity
site
therapy
tolerability profile
treatment
trial patient
ALLO Transcript
Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call Transcript
Unknown5-14
The earnings call presents a mix of positive and negative indicators. The company's strategic focus on innovative cancer therapies and strong market trends are promising. However, the lack of specific revenue guidance and increased expenses raise concerns. The Q&A section reveals positive enrollment and safety profile feedback, but management's vague responses on certain issues may cause uncertainty. Overall, the neutral sentiment reflects the balance between potential growth and existing uncertainties.
Allogene Therapeutics, Inc. (ALLO) Q4 2025 Earnings Call Transcript
Unknown3-13
The earnings call presents a mixed picture. Financial performance shows improvement with a 25% revenue increase and reduced net loss. However, the lack of specific revenue guidance and the absence of a shareholder return plan create uncertainties. Strategic initiatives are promising, but the absence of clear risk assessment and operational updates limits positive sentiment. The overall neutral sentiment is due to balanced positive financial metrics and growth expectations against the lack of clarity in guidance and shareholder returns.
European Residential Real Estate Investment Trust (ERE.UN:CA) Q3 2025 Earnings Call Transcript
Unknown11-7
The earnings call reveals several concerns: declining residential occupancy and NOI margin, ongoing tax reassessments, and uncertainty surrounding the disposition strategy and timeline. Despite a special cash distribution and debt reduction, the lack of clear guidance on the REIT wrap-up and declining profitability metrics weigh heavily. The Q&A session highlighted management's evasiveness on key issues, further contributing to a negative sentiment. The market is likely to react negatively, expecting a stock price decrease in the range of -2% to -8%.
Allogene Therapeutics, Inc. (ALLO) Q3 2025 Earnings Call Transcript
Unknown11-7
The earnings call reveals mixed signals. While the company has promising trial data and a solid cash runway, it also faces significant cash burn and a net loss, raising concerns about financial sustainability. The Q&A section indicates steady progress in trials but lacks detailed guidance, which might worry investors. The absence of any major new partnerships or positive shareholder return announcements tempers optimism. These factors suggest a neutral stock price movement over the next two weeks.
ALLO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
